Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bladder cancer study could reduce need for repeated surgeries

NCT ID NCT06781879

Disease control Sponsor: Jakob Kristian Jakobsen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug treatment (chemoablation) can replace surgery for people with a common, recurring type of bladder cancer. About 272 adults with small, low-grade tumors that came back will either get the drug or standard surgery plus additional therapy. The goal is to see which approach better prevents the cancer from returning over two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 272 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Feb 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Tumour recurrence after previous urothelial tumour of Ta low-grade * Tumours smaller than 2 cm in diameter * Negative urine cytology (optional) * ≥18 years of age * Ability to understand and comprehend the provided written and oral information * Has provided written consent Exclusion Criteria: * Known history of invasive tumour of the bladder (T1+) * Known history of CIS of the bladder * Previous MMC or BCG-treatment except for single instillations following previous TURBTs * Known allergy or intolerance to MMC * Solid tumour with suspicions of invasion * Tumour in the bladder neck or urethra * Suspicion of CIS (positive cytology with high-grade neoplastic cells combined with suspicious flat lesions seen at cystoscopy) * Small bladder volume (less than 100 ml) or incontinence * Prior radiation therapy to the pelvic area, as radiation affects the bladder function and instillation therapy is a suboptimal treatment for this patient group * Acute cystitis * Pregnancy or breast-feeding * Averse to using secure contraception with regard to men with partners and premenopausal women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-muscle invasive bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-muscle invasive bladder cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    NOT_YET_RECRUITING

    Aalborg, Denmark

  • Aarhus University Hospital

    RECRUITING

    Aarhus N, 8200, Denmark

  • Haukeland University Hospital

    NOT_YET_RECRUITING

    Bergen, Norway

  • Herlev and Gentofte Hospital

    RECRUITING

    Herlev, Denmark

  • Landspítali University Hospital

    NOT_YET_RECRUITING

    Reykjavik, Iceland

  • NU Hospital Group

    NOT_YET_RECRUITING

    Uddevalla, Sweden

  • Vestfold Hospital Trust

    NOT_YET_RECRUITING

    Tønsberg, Norway

  • Zealand University Hospital, Roskilde

    RECRUITING

    Roskilde, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.